Cripto antagonism of activin and TGF-b signaling
US9546210B2 · kind B2 · utility
1Cited by
3References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 21, 2010 |
| Grant date | Jan 17, 2017 |
| Priority date | — |
| Expiry date | Sep 13, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/82
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.